École de la SEP, Mulhouse, décembre 2021.
École de la SEP, Strasbourg, décembre 2021.
École de la SEP, Villeurbanne, en cours.
Article en anglais :
As a temporary measure while the review is ongoing, Lemtrada should only be started in adults with relapsing-remitting multiple sclerosis that is highly active despite treatment with at least two disease-modifying therapies (a type of multiple sclerosis medicine) or where other disease-modifying therapies cannot be used. Patients being treated with Lemtrada who are benefitting from it may continue treatment in consultation with their doctor.
Dossier : Lemtrada.